FDA

Release: Fluoxetine Increases Aggressive Behavior, Affects Brain Development Among Adolescent Hamsters

Story Banner Melloni

Fluoxetine was the first drug approved by the FDA for major depressive disorder (MDD) in children and adolescents, and to this date, it remains one of only two selective serotonin reuptake inhibitors (SSRIs) registered for treatment of MDD in children and adolescents, despite reports that indicate this class of drugs is associated with side effects, such as agitation, hostility and aggression.

Tagged with: , , , ,
Posted in Behavioral Neuroscience, Press Releases